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Introduction
Juvenile nasopharyngeal angiofibroma 
(JNA) is defined to be benign and locally aggressive 
vascular tumor, affecting adolescent males [1]. JNA is 
responsible for 0.5% of head and neck tumors. Although 
this tumor is considered to be commonly occurred in 
nasopharynx, there are reports of its presence in the 
nasal septum, inferior and middle turbinate, hard palate, 
and alveolar ridge [2], [3], [4], [5], [6]. The prevalence 
of JNA is estimated to be 1/150,000–1/1,500,000 
individuals [7], [8], [9], [10]. Previous studies indicated 
that disease was more prevalent in the Indian 
and Middle Eastern populations as compared to 
European populations [11]. Diagnosis of the tumor is 
usually based on the location of origin, post-contrast 
hypervascularization, and growth patterns [12], [13]. 
JNA typically receives vascular nutrition from the 
external carotid system, especially the internal maxillary, 
ascending pharyngeal, and vidian arteries [14], where 
vessels from the branches of the internal carotid artery, 
such as the Inferior hypophyseal artery, are commonly 
found in lesions involving the cranial base [15].
Many therapeutic modalities have been applied 
for treating this tumor. Non-surgical treatments include 
the use of hormones (estrogen and testosterone), 
radiotherapy, chemotherapy, and more recently 
embolization. Surgery and radiotherapy are among the 
most effective procedures [16], [17], [18]. Surgery is the 
therapeutic choice based on the stage of the tumor and 
the patient’s general condition. For many years, several 
acceptable numerous approaches have been applied for 
decreasing morbidity and mortality of tumors. There are 
various opinions regarding the pre-operative embolization 
in the surgical treatment of this tumor; some surgeons 
believed that embolization was acceptable method, while 
others oppose it [19], [20], [21], [22], [23]. Pre-surgical 
tumor embolization for hypervascular neoplasms results 
in improved surgical outcomes reduced intraoperative 
bleeding and facilitating tumor resection [24]. Polyvinyl 
alcohol is the most commonly used embolization material 
that should be performed 24–48 h before surgery for 
avoiding revascularization [15].
Studies have shown that bilateral embolization 
of the internal maxillary artery was capable of improving 
treatment efficacy when the tumor received blood from 
bilateral external carotid artery [25]. In the past, to 
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control bleeding originating from the internal carotid 
artery in a lesion with extensive skull base involvement, 
a direct transcutaneous lateral embolization technique 
with a combination of cyanoacrylate, lipiodol, and 
tungsten powder was proposed [26].
Some recent reports have introduced embolic 
agent Onyx with a non-migratory and bleeding-reducing 
property that has significant therapeutic performance, 
where the interest in this new treatment has 
increased [27], [28]. Due to the complications of pre-
operative embolization, this study aimed to reduce 
the amount of bleeding during surgery and improve 
visual acuity, and to minimize the complications of pre-
operative embolization and costs.
Materials and Methods
Between 2012 and 2014, 30 patients with 
angiofibroma undergoing endoscopic surgery in ear, 
nose, and throat department of Amir A’lam Hospital 
were enrolled in the study.
Exclusion criteria included pregnancy, history 
of malignancy, history of previous surgery, patients 
with Stage IIc above, and patients with other systemic 
diseases such as Wagner’s disease. All patients were 
included in the study with written consent. However, 
due to ethical considerations, patient information was 
kept confidential. All patients were radiologically and 
surgically classified with Radkowski staging system.
Thirty patients were divided into three groups. 
The patient group (Group 1) consisted of 10 patients 
who underwent endoscopic surgery with surgical 
Glubran glue. The control group (Group 2) consisted 
of 10 patients without surgical glue and embolization. 
The third group (Group 3) consisted of 10 patients who 
underwent embolization surgery. Groups were matched 
for such factors as sex, age range, and stage of the 
tumor by propensity score matching method.
Methods
After the patients under hypotensive anesthesia, 
0.5 cc glue was injected with normal saline for the patients 
group. It is worth noting that 0.5 cc surgical glue Glubran 
in combination with n-butyl 2-cyanoacrylate adhesive 
was used. Subsequently, tumor bulk was pushed into 
the nasopharyngeal space by a medium-sized FREER 
Septum Elevator and adrenaline soaked on gauze. 
Then, the surgical process continued, depending on 
the tumor spread. For example, in the case of tumor 
expansion to the pterygomaxillary fissure, surgery was 
performed by removing the posterior wall of the maxillary 
sinus and pushing it toward the medial side. If the tumor 
had a lateral extension to infratemporal fossa, force was 
applied from the lateral to the medial with the freer and 
gauze. Surgical meshes were used for cavernous sinus 
bleeding while the anesthesia team was ready to treat 
severe bleeding. The mass was completely removed by 
the use of DAVIS Mouth Gags and large-size forceps 
after pushing the bulk of the tumor into the nasopharynx 
and the oropharynx. Suction electrocautery and bipolar 
were used for homeostasis. These tumors were never 
resected in a piecemeal manner. At the end of the 
operation, an examination of the remaining tissues and 
sites of abnormal bleeding was performed. In addition, 
all surgeries are performed by one surgeon.
Prophylactic drilling of the clivus or pterygoid 
root and sphenoid diploe and vidian canal was 
also performed on patients who had obvious bone 
involvement in these locations.
Evaluation of bleeding rate, injection 
blood, and duration of hospitalization
All patients were compared regarding the 
amount of intraoperative bleeding, the amount of tumor 
bleeding based on the surgeon’s opinion, the amount 
of blood transfused the length of stay after surgery, 
complications, amount of residual tumor, and recurrence. 
The volume of intraoperative bleeding was calculated 
based on the counting number of blooded gauze and 
the volume of suctioned blood. All patients undergoing 
endoscopic angiofibroma surgery were evaluated 
endoscopically 2 weeks after surgery, and then evaluated 
for the first 6 months monthly and then annually. 
A computed tomography (CT) evaluation was performed 
in the 3rd month after surgery. If endoscopic abnormalities 
were seen during the examination of recurrent patients, 
the findings were confirmed by contrast-enhanced CT 
(CECT). Diagnosis of recurrent angiofibroma was also 
assessed based on clinical symptoms and CECT scans 
and sometimes magnetic resonance imaging. The mean 
follow-up period was 8.8 ± 3.16 for Group 1 followed by 
24.3 ± 17.56 months for Group 2 and 10 ± 7.53 months 
for Group 3.
Statistical analysis
After data collection, the Data Bank was 
prepared by SPSS software version 19 and the data 
were entered. T-test was used to compare the results. In 
all cases, p < 0.05 was considered statistically significant.
Results
In this study, 30 patients underwent surgery, all 
of whom were male. The mean age of Group 1 was 
18.5 ± 5.56 followed by 18.2 ± 5.56 for Group 2 and 
17.5 ± 4.10 for Group 3. Patients in each group had 
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Stage IIc (9 patients) and IIb (1 patient). The three 
groups were matched for age, sex, and stage of the 
disease (Table 1).
Table 1: Characteristics of the three groups of patients with 
angiofibroma according to sex, sex, and stage of disease
Character Group 1 Group 2 Group 3 p-value
Age 18.5±5.56 18.2±5.06 17.5±4.10 0.907
Sex Female Male Female Male Female Male 1
0 10 0 10 0 10
Disease stage IIc IIb IIc IIb IIc IIb 1
9 1 9 1 9 1
As can be seen in Table 2, the most common 
symptom was a nasal obstruction in 29 patients (96.7%) 
followed by epistaxis in 18 patients (60%). One patient 
also had a headache (3.3%).
Table 2: The most common clinical symptoms of angiofibroma 
patients at the time of referral based on the three groups
Frequency of clinical symptoms at the time of referral
Studied groups Frequency of nasal 
obstruction (%)
Epistaxis 
frequency (%)
Headache 
Frequency (%)
The first group (surgical 
technique using glue)
10 (100) 6 (60) 0
The second group (surgery 
without the use of glue and 
embolization)
9 (90) 7 (70) 1 (10)
The third group (surgery with 
pre-operative embolization)
10 (100) 5 (50) 0
All patients 29 (96) 18 (60) 1 (3.3)
The number of people with mild, moderate, 
and severe bleeding is shown in Figure 1. In terms of 
bleeding rates, the average bleeding in Groups 1, 2, and 
3 was determined as 510 cc, 1655 cc, and about 800 
cc, respectively. There was a significant difference in the 
amount of bleeding between Groups 1 and 2 (p = 0.007) 
and Groups 2 and 3 (p = 0.048). Bleeding in Group 1 
was lower than in Group 3, but there was no significant 
difference between Groups 1 and 3 (p = 0.678). In 
Group 1, no blood unit was injected. The difference 
between Group 1 and 2 was significant (p = 0.004). 
Figure 1: Number of people with mild, moderate, and severe bleeding 
depending on the surgeon’s view for severity of bleeding
Analysis of hospital stay variables showed no 
significant difference between groups (Table 3). Mean 
days of hospitalization in Group 1 were 2.1 ± 0.32 
Table 3: Number of admission days after surgery in three 
groups of angiofibroma patients
Patients The number of hospitalization days
1–2 day >2 day
Group 1 9 1
Group 2 6 4
Group 3 8 3
Significant p=0.09
followed by 2.4 ± 0.84 in Group 2 and 2.3 ± 0.48 days 
in Group 3. The mean days of admission were lower in 
Group 1.
The mean follow-up period for Group 1 was 
8.8 ± 3.16 months followed by 24.3 ± 17.56 months 
for Group 2 and 10 ± 7.53 months for Group 3. The 
recurrence rate in Group 1 was 0% and Groups 2 and 
3 each had one recurrent patient (10%). An 18-year-
old patient was recorded for Group 2 and a 13-year-old 
patient for Group 3, both of whom were in Stage IIc. 
There was no significant difference in the recurrence 
rate between Groups 1 and 2 and 3 (p = 0.754).
Discussion
The direct percutaneous approach using liquid 
embolic materials such as glue or onyx is the most widely 
used approach. The benefits of onyx over glue are 
primarily due to the slower rate of polymerization which 
allows deeper penetration within the tumor vasculature, 
in contrast to the instant polymerization of glue on 
contact with blood that prevents uniform and controlled 
penetration of the tumor vasculature [27], [29].
Another liquid embolic agent commonly used 
in practice is Fibrin. Fibrin glue has been used in 
neurosurgery, pharmacology, vascular surgery, pre-
operative embolization of the patient with intracranial 
meningioma, closure of the dura, and prevention of 
spinal fluid leaks [30]. In addition, fibrin glue spray 
has been effective in fixing mucoperichondrium to 
cartilage instead of suture [31]. The present study 
investigated the effect of glue on post-operative 
health factors of patients. According to our findings, 
the amount of bleeding was lowest in the group with 
glue, where the complications of blood transfusion 
were minimal.
Intraoperative use glue appears to block 
intratumor vessels and reduces intraoperative 
hemorrhage while it may be a useful measure to 
reduce bleeding in tumors with bilateral blood supply 
and internal carotid blood supply. The use of embolic 
agents has played an important role in the treatment of 
patients [27], [28]. Elhammady et al. have compared pre-
operative transarterial embolization and embolization 
with onyx via direct tumoral puncture [32].
However, it should be noted that 
complications after the use of embolic agents are 
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important, and all studies on embolization have not 
been fully successful [26]. Ethylene-vinyl alcohol 
copolymer embolic agent has been studied for the 
direct percutaneous embolization of angiofibroma 
with complications such as trigeminal cardiac 
reflex [33], [34], [35]; however, the advantage of 
onyx is the absence of side effects and a positive 
effect on bleeding [29]. The success criteria for any 
tumor surgery is depend on the recurrence rate. The 
recurrence rate of angiofibroma has been reported in 
some studies (7–39.5%) [36] and some studies have 
reported a recurrence rate of 25–46%, where a rate of 
25% was reported for Stage IIc and 40–50% for Stage 
III [37], [38], [39], [40]. In our study, no recurrence was 
seen in Group 1 that is different from other studies; this 
difference may be related to the selection of patients 
with Stage IIc (below). In a recent study, three factors 
were predictive of a recurrence rate that including 
patient under 18 years of age at diagnosis, tumor size 
>4 cm, and advanced stage of disease, according to 
Radkowski’s classification [41].
Our findings should take into consideration in 
light of limitations regarding a relatively short follow-up 
period of patients after surgery. Although most 
symptomatic relapses are expected to occur during the 
first 12 months after treatment [42], this can certainly be 
debated. Fibrin glue had a positive effect on reducing 
bleeding and requiring blood transfusion, which has 
been the main finding of our study.
There are a number of limitations to our 
study. In the first place, the number of cases included 
in this study is somewhat small which makes the 
generalization of results not possible. There is also 
some minor inaccuracy in estimated intraoperative 
blood loss due to the fact that adjustment is made for 
the surgical effluent containing both fresh blood and 
operative irrigation fluid.
Finally, it may be suggested that comprehensive 
studies are required with longer follow-up, and it is hoped 
that this method will be used as a routine technique in 
future angiofibroma operations.
Conclusions
The direct embolization technique using 
surgical glue allows for more complete and targeted 
tumor embolization. The main advantage of this 
technique is the ease of procedure with a spinal 
needle which was associated with reduced exposure 
to radiation, less intraoperative bleeding, and lower 
cost. In addition, surgical glue injection can be used 
in all vascular tumors of the sinus cavities as a 
research and its application in tumor recurrence and 
advanced stages of angiofibroma tumor can also be 
evaluated.
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